PT-141 (Bremelanotide) Off-Label Uses with Evidence Levels

How Bremelanotide Works: The Melanocortin Pathway

Bremelanotide activates melanocortin-4 receptors (MC4R) in the medial preoptic area and paraventricular nucleus of the hypothalamus, regions that integrate sexual motivation and autonomic arousal. Unlike phosphodiesterase-5 inhibitors (sildenafil, tadalafil), which act on peripheral vascular smooth muscle, bremelanotide modulates the central nervous system pathway upstream of genital hemodynamics.

The drug is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). After subcutaneous injection, peak plasma concentration occurs at approximately 1 hour, with a terminal half-life of 2.7 hours 1. MC4R activation triggers downstream oxytocin and dopamine release in mesolimbic circuits, producing increases in subjective desire rather than reflexive vasodilation alone. This central mechanism explains why bremelanotide can affect desire, arousal, and orgasm across both sexes, and why off-label interest extends beyond the narrow HSDD label.

Animal knockout studies demonstrated that MC4R-null mice show abolished sexual motivation despite intact erectile reflexes 2. That dissociation between desire and mechanics is the pharmacological rationale for every off-label application discussed below.

Off-Label Use #1: Male Erectile Dysfunction

The strongest off-label evidence exists for erectile dysfunction (ED) in men. A Phase IIb randomized, double-blind, placebo-controlled trial (N=342) tested subcutaneous bremelanotide at doses of 0.3 mg, 1.0 mg, and 4.0 mg in men with mild-to-moderate ED who had not responded adequately to sildenafil 3.

Results at the 4.0 mg dose showed a statistically significant improvement in the International Index of Erectile Function (IIEF) erectile domain score versus placebo (mean difference +3.2 points, P=0.018). Response rates were 40.4% for the 4 mg group compared with 23.1% for placebo. The 1.0 mg dose did not separate from placebo.

A separate open-label study of intranasal bremelanotide (since abandoned due to blood pressure concerns with the nasal route) in 20 men with ED demonstrated erections sufficient for intercourse in 13 of 20 participants within 45 minutes of dosing 4.

Evidence grade: Moderate (Phase IIb RCT, not replicated in Phase III).

The manufacturer did not pursue a Phase III ED program. Clinicians prescribing off-label for male ED typically use the 1.75 mg subcutaneous dose (the approved female HSDD dose) and titrate to effect, though no male-specific dosing guideline exists.

Off-Label Use #2: SSRI-Induced Sexual Dysfunction

Selective serotonin reuptake inhibitors cause sexual dysfunction in 40-65% of users, per a systematic review in the Journal of Clinical Psychiatry 5. Because bremelanotide acts on a pathway independent of serotonin reuptake, it represents a mechanistically logical intervention.

A Phase II randomized crossover trial (N=62) evaluated bremelanotide 1.75 mg versus placebo in premenopausal women with SSRI-induced low desire and arousal. The primary endpoint, satisfying sexual events (SSEs) over 4 weeks, increased by 0.7 events per month in the bremelanotide arm versus placebo (P=0.042) 6.

For men on SSRIs, only case-series data (N<20) exist. One published case series of 8 men on paroxetine or sertraline reported that 6 achieved satisfactory erections with subcutaneous bremelanotide 1.75 mg when PDE5 inhibitors had failed 7.

Evidence grade: Moderate for women (Phase II RCT), Low for men (case series only).

Off-Label Use #3: Female Arousal Disorder and Anorgasmia

The RECONNECT trials (two identically designed Phase III studies, combined N=1,247) demonstrated that bremelanotide improved not only desire but also arousal scores on the Female Sexual Function Index (FSFI) 1. The arousal domain improvement was a secondary endpoint: +0.7 points over placebo on the FSFI arousal subscale (P<0.01).

For isolated female orgasmic disorder (anorgasmia without low desire), a single-arm pilot study (N=18) at the University of Virginia tested bremelanotide 1.75 mg in women with lifelong anorgasmia. Nine of 18 women (50%) reported their first orgasm during the 12-week treatment period 8. The study lacked a placebo arm, which limits interpretation.

A subgroup analysis from RECONNECT showed that women with comorbid arousal complaints had a larger treatment effect (FSFI total score difference of 4.2 points vs. 2.8 in the intent-to-treat population), suggesting bremelanotide may be particularly effective when arousal deficits accompany desire deficits 1.

Evidence grade: Low-to-Moderate for arousal disorder (secondary endpoint in Phase III), Very Low for isolated anorgasmia (uncontrolled pilot).

Off-Label Use #4: Hemorrhagic Shock Resuscitation

An unexpected pharmacological application emerged from preclinical work. MC4R agonists, including bremelanotide, demonstrated potent vasopressor and anti-inflammatory effects in rodent hemorrhagic shock models. A 2015 study in Critical Care Medicine showed that a single IV dose of bremelanotide (80 μg/kg) restored mean arterial pressure in rats with uncontrolled hemorrhage and reduced 24-hour mortality from 78% to 32% 9.

The mechanism involves MC4R-mediated inhibition of NF-κB signaling in vascular endothelium, reducing capillary leak and systemic inflammatory response. No human trials have been conducted for this indication. The Feinstein Institutes for Medical Research holds a separate patent on melanocortin peptides for trauma resuscitation.

Evidence grade: Very Low (preclinical only, no human data).

Off-Label Use #5: Obesity and Appetite Regulation

MC4R is a validated target in energy homeostasis. Loss-of-function MC4R mutations are the most common monogenic cause of obesity, affecting approximately 5% of severely obese individuals 10. Bremelanotide's MC4R agonism raised early interest as an anti-obesity agent.

However, Phase I data showed that the 1.75 mg subcutaneous dose did not produce clinically meaningful appetite suppression or weight loss over 28 days. Setmelanotide (Imcivree), a more selective MC4R agonist developed specifically for genetic obesity, received FDA approval in 2020 for POMC, PCSK1, and LEPR deficiency obesity. Bremelanotide's non-selective melanocortin profile and short half-life make it pharmacologically inferior for chronic weight management.

Evidence grade: Not applicable (mechanism plausible, but superseded by setmelanotide; no clinical development program).

Off-Label Use #6: Postmenopausal Sexual Dysfunction

The FDA approval for bremelanotide explicitly excludes postmenopausal women. The RECONNECT trials enrolled only premenopausal patients. However, a dedicated Phase II trial (the "Bremelanotide in Postmenopausal Women" study, N=327) was completed in 2017. Results showed a statistically significant increase in SSEs versus placebo (+0.5 events/month, P=0.038), though the magnitude of benefit was smaller than in premenopausal cohorts 11.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "data in postmenopausal women are limited and do not yet support a recommendation" for bremelanotide in this population 12.

Clinicians who prescribe off-label for postmenopausal patients typically combine bremelanotide with local estrogen therapy for vaginal atrophy, addressing both central desire and peripheral tissue health simultaneously.

Evidence grade: Moderate (Phase II RCT with positive primary endpoint, no Phase III confirmation).

Comparative Evidence Summary Table

| Off-Label Indication | Study Design | Sample Size | Effect vs. Placebo | Evidence Grade | |---|---|---|---|---| | Male ED | Phase IIb RCT | 342 | IIEF +3.2 (P=0.018) | Moderate | | SSRI-induced dysfunction (women) | Phase II crossover | 62 | +0.7 SSE/month (P=0.042) | Moderate | | Female arousal disorder | Phase III secondary endpoint | 1,247 | FSFI arousal +0.7 (P<0.01) | Low-Moderate | | Postmenopausal HSDD | Phase II RCT | 327 | +0.5 SSE/month (P=0.038) | Moderate | | Female anorgasmia | Open-label pilot | 18 | 50% first orgasm | Very Low | | Hemorrhagic shock | Preclinical | N/A (rodent) | MAP restored, mortality ↓ | Very Low | | Obesity | Mechanistic only | N/A | No clinical program | Not applicable |

Safety Considerations for Off-Label Prescribing

Nausea occurs in approximately 40% of patients at the 1.75 mg dose, typically resolving within 2 hours. In the RECONNECT trials, 13% of bremelanotide-treated patients discontinued due to nausea versus 1% on placebo 1.

Transient blood pressure elevation (mean +6 mmHg systolic, +3 mmHg diastolic) peaks at 2-3 hours post-dose. The FDA label carries a warning against use in patients with uncontrolled hypertension or cardiovascular disease. For off-label male ED use, this is particularly relevant because the target population overlaps significantly with the cardiovascular disease population.

Skin hyperpigmentation has been reported with repeated dosing, particularly in darker-skinned individuals. The mechanism involves MC1R cross-activation stimulating melanogenesis. In the 60-week open-label extension of RECONNECT, focal hyperpigmentation occurred in 1.2% of subjects 1.

The FDA restricts dosing to no more than 8 doses per month and no more than 1 dose per 24 hours. Off-label prescribers should maintain these limits regardless of indication.

How PT-141 Differs from PDE5 Inhibitors

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) block the degradation of cyclic GMP in penile corpus cavernosum smooth muscle. They require sexual stimulation to initiate the nitric oxide cascade. Bremelanotide acts upstream in the hypothalamus, independently of peripheral genital mechanisms. This distinction matters clinically: patients who fail PDE5 inhibitors due to low desire rather than vascular insufficiency represent the logical off-label bremelanotide candidate population.

A head-to-head comparison has never been conducted. The Phase IIb ED trial specifically enrolled PDE5 inadequate responders, and the positive results in that population suggest a complementary rather than competing mechanism 3.